Kaken Pharmaceutical Company, Ltd.

Molecular Research Institute

Satoru Ikegami

Ping Huang

Nobuo Ishiyama

Kiyoshi Inoguchi

Tadashi Okuno

Hidenori Funamizu

Gilda Loew

Atsushi Watanabe

Tadashi Ohyama

Yoichiro Hoshina

Kimio Hirano

Atsushi Matsuo

Mitsuo Mimura

Yoshitaka Ohishi

Mitsuo Hayashida

Keigo Hanada

Tatsuhiro Harada

Yoshiyuki Hiyama

Makoto Tamura

Kiyonoshin Ichikawa

Akihiko Okuyama

Takao Awa

Kiyoshi Nomiyama

There are provided 4-alkynylimidazole derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof; the derivatives have a superior EP4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the EP4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of Th1 cells and/or Th17 cells: 

4-alkynyl imidazole derivative and medicine comprising same as active ingredient

The present invention relates to a 2-phenyl-3-heteroarylpropionic acid derivative or a salt thereof, and also relates to a pharmaceutical agent and a VLA-4 and/or LPAM-1 antagonist each of which contains the same as an active ingredient.

2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same

A 2,3-diphenylpropionic acid derivatives or the salts represented by general formula (1) below; and pharmaceutical compositions and cell adhesion inhibitors comprising the derivatives or the salts as the active ingredient. In the formula, A, B and C independently represents a hydrogen atom or a monovalent substituent; and X and X' independently represents a hydrogen atom or a monovalent substituent 

2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage

Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals 

Amide derivatives

N-acylated lipophilic amino acid derivatives

Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals

A bisphosphonic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein A is ##STR2## each of R.sup.3 and R.sup.4, which may be the same or different, is (i) a hydrogen atom, (ii) a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkyl-carbonyl group, a C.sub.2-6 alkenyl-carbonyl group, a C.sub.2-6 alkynyl-carbonyl group R.sup.5 and R.sup.6, which may be the same or different, is a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, a carbamoyl group, an aralkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted amino group, a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group;

Bisphosphonic acid derivatives, as bone resorption inhibitors

Growing community of inventors

Kyoto, Japan

Satoru Ikegami